SG11202112478PA - Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides - Google Patents

Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides

Info

Publication number
SG11202112478PA
SG11202112478PA SG11202112478PA SG11202112478PA SG11202112478PA SG 11202112478P A SG11202112478P A SG 11202112478PA SG 11202112478P A SG11202112478P A SG 11202112478PA SG 11202112478P A SG11202112478P A SG 11202112478PA SG 11202112478P A SG11202112478P A SG 11202112478PA
Authority
SG
Singapore
Prior art keywords
coformulations
sglt2 inhibitors
cyclodextrin based
based injectable
incretin peptides
Prior art date
Application number
SG11202112478PA
Inventor
Anne-Laure Laine
Lutz Jermutus
Dos Santos Ana Gomes
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of SG11202112478PA publication Critical patent/SG11202112478PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SG11202112478PA 2019-05-21 2020-05-20 Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides SG11202112478PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962850710P 2019-05-21 2019-05-21
PCT/EP2020/064128 WO2020234384A1 (en) 2019-05-21 2020-05-20 Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides

Publications (1)

Publication Number Publication Date
SG11202112478PA true SG11202112478PA (en) 2021-12-30

Family

ID=70857161

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112478PA SG11202112478PA (en) 2019-05-21 2020-05-20 Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides

Country Status (14)

Country Link
US (1) US20220249617A1 (en)
EP (1) EP3972630A1 (en)
JP (1) JP2022533674A (en)
KR (1) KR20220010553A (en)
CN (1) CN113840619A (en)
AR (1) AR118977A1 (en)
AU (1) AU2020280905A1 (en)
BR (1) BR112021023012A2 (en)
CA (1) CA3139613A1 (en)
EA (1) EA202193102A1 (en)
IL (1) IL287996A (en)
SG (1) SG11202112478PA (en)
TW (1) TW202110473A (en)
WO (1) WO2020234384A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114470170B (en) * 2022-02-22 2023-09-19 广州新济药业科技有限公司 Semiglutide soluble microneedle composition and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100009907A1 (en) * 2006-07-06 2010-01-14 Amylin Pharmaceuticals, Inc. Glucagon-Like Peptides and Uses Thereof
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TWI674270B (en) 2012-12-11 2019-10-11 英商梅迪繆思有限公司 Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201806342SA (en) * 2016-03-10 2018-08-30 Medimmune Ltd Glucagon and glp-1 co-agonists for the treatment of obesity
EP3551290A4 (en) * 2016-12-12 2020-12-23 GI Dynamics, Inc. Therapeutic methods involving gastrointestinal implants

Also Published As

Publication number Publication date
AR118977A1 (en) 2021-11-17
IL287996A (en) 2022-01-01
EP3972630A1 (en) 2022-03-30
CN113840619A (en) 2021-12-24
KR20220010553A (en) 2022-01-25
WO2020234384A1 (en) 2020-11-26
JP2022533674A (en) 2022-07-25
US20220249617A1 (en) 2022-08-11
TW202110473A (en) 2021-03-16
CA3139613A1 (en) 2020-11-26
BR112021023012A2 (en) 2022-01-04
EA202193102A1 (en) 2022-02-17
AU2020280905A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
IL275333A (en) Inhibitors of fibroblast activation protein
IL282487A (en) Tyk2 inhibitors and uses thereof
IL282252A (en) Indole ahr inhibitors and uses thereof
EP3227310A4 (en) Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
IL286248A (en) Tyk2 inhibitors and uses thereof
IL284799A (en) Tyk2 inhibitors and uses thereof
IL282090A (en) Tyk2 inhibitors and uses thereof
IL272649B (en) Ahr inhibitors and uses thereof
IL283409A (en) Tyk2 inhibitors and uses thereof
ZA202006092B (en) Imidazopiperazine inhibitors of transcription activating proteins
EP3898654A4 (en) Inhibitors of fibroblast activation protein
IL280051A (en) Ep4 inhibitors and synthesis thereof
EP3638369A4 (en) Compositions and methods for treatment of netherton syndrome with lekti expressing recombinant microbes
EP3688011A4 (en) Peptide compositions and methods of use thereof
IL289622A (en) Bcl-2 protein inhibitors
EP3642219A4 (en) Peptide compositions and related methods
EP3288379A4 (en) Peptide compositions and methods of use
EP3897670A4 (en) Inhibitors of sarm1 in combination with neuroprotective agents
IL284434A (en) Inhibitors of fibroblast activation protein
PT3712147T (en) Sglts inhibitor and application thereof
EP4069274A4 (en) Peptide conjugates and methods of use
EP3125906A4 (en) Peptide fragments of netrin-1 and compositions and methods thereof
EP3678660A4 (en) Trpc5 inhibitors and methods of using same
IL287996A (en) Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides
IL286485A (en) Pi4-kinase inhibitors and methods of using the same